Dr David Propper
Honorary Group Leader
Jump to Section
Overview
Our group researches pancreatic tumour-stromal interactions and reprogramming in 3D and other laboratory models. We also focus on translational trials of stromal reprogramming, including through epigenetic targeting, immune therapies, and cytokine gene therapy.
Research
Our group researches pancreatic tumour-stromal interactions and reprogramming in 3D and other laboratory models. We also focus on translational trials of stromal reprogramming, including through epigenetic targeting, immune therapies, and cytokine gene therapy.
Key Publications
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat Commun (2020) 24;11(1):4841. PMID: 32973176
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br J Cancer (2020) 122, 1760-1768. PMID: 32350413
Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut (2019) 68(6):1052-1064. PMID: 30121627
The VAR2CSA malaria protein efficiently retrieves circulating tumor cells in an EpCAMindependent manner. Nat Commun (2018) 9(1):3279. PMID: 30115931
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol (2018) 19(4):562-578. PMID: 29611518